What Happened
- India called for enhanced collaboration with Switzerland in research and development, biotechnology, and pharmaceutical innovation during high-level bilateral discussions
- Commerce Minister Piyush Goyal met with Swiss State Secretary for Economic Affairs to advance cooperation
- Focus areas include: joint research initiatives, regulatory alignment, clinical innovation, advanced manufacturing, and shortened drug development timelines
- Industry-academia partnerships, technology transfer, start-up engagement, and high-value pharmaceutical manufacturing were identified as key cooperation areas
- Regulatory agencies from both nations discussed cooperation in safety evaluation, quality standards, and scientific exchange for emerging areas such as cell and gene therapies, digital health-integrated therapeutics, and complex generics
Static Topic Bridges
India-EFTA Trade and Economic Partnership Agreement (TEPA)
India signed the Trade and Economic Partnership Agreement with the European Free Trade Association (EFTA) states — Switzerland, Norway, Iceland, and Liechtenstein — in 2024. This agreement is the first comprehensive trade pact between India and a European economic bloc and includes significant provisions on investment, intellectual property, and services.
- EFTA committed to facilitating USD 100 billion in investment in India over 15 years, with potential to create 1 million direct jobs
- The agreement includes intellectual property provisions: a non-discrimination clause ensures imported Swiss products receive the same patent protection as locally manufactured goods
- TEPA preserves India's right to grant compulsory licenses under the TRIPS Agreement for pharmaceutical products
- Patent opposition proceedings must be processed within "reasonable time" and unfounded oppositions swiftly rejected
- Controversial provisions: Switzerland initially sought regulatory data exclusivity of at least 6 years, which would go beyond WTO TRIPS requirements and could impact access to affordable generic medicines
- The agreement is expected to come into force by 2025-2026, pending parliamentary ratification in respective countries
Connection to this news: The bilateral R&D and pharma cooperation discussions build on the TEPA framework, which provides the institutional and legal basis for deeper economic integration between India and Switzerland, particularly in the pharmaceutical sector where both nations have complementary strengths.
India's Pharmaceutical Sector — "Pharmacy of the World"
India is the world's largest producer of generic medicines, supplying approximately 20% of global generic drug output by volume. The sector is valued at over USD 50 billion in exports and is underpinned by the Indian Patents Act, 1970, which historically did not recognise product patents for pharmaceuticals — a deliberate policy choice that enabled the growth of the generic industry.
- India's pharma exports: approximately USD 28 billion (2024-25), with the US and EU as primary markets
- Section 3(d) of the Patents Act, 1970 (inserted by the 2005 amendment): prevents "evergreening" of patents by refusing patents for new forms of known substances unless they demonstrate significantly enhanced efficacy — upheld by the Supreme Court in Novartis v. Union of India (2013)
- Compulsory licensing: Section 84 of the Patents Act allows compulsory licenses after 3 years if the patented product is not available at a "reasonably affordable price" — invoked once for Bayer's Nexavar (2012) by the Controller General of Patents
- TRIPS Agreement compliance: India transitioned to a product patent regime in 2005 (as mandated by the WTO TRIPS Agreement), while retaining flexibilities like Section 3(d) and compulsory licensing
- The Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers is the nodal ministry
Connection to this news: The India-Switzerland pharma cooperation is strategically significant because Switzerland houses global pharma giants (Roche, Novartis, Nestlé Health Science) while India's generic manufacturing capability is unmatched, creating complementary value chains for drug development and distribution.
Biotechnology Policy and Regulatory Framework in India
India's biotechnology sector is governed by a multi-layered regulatory framework involving multiple agencies. The sector is valued at over USD 80 billion and is one of the fastest growing globally, with applications in biopharmaceuticals, agricultural biotech, industrial biotech, and medical devices.
- Regulatory bodies: Department of Biotechnology (DBT, est. 1986) under the Ministry of Science and Technology; Genetic Engineering Appraisal Committee (GEAC) under MoEFCC for environmental releases
- The Biotechnology Regulatory Authority of India (BRAI) Bill, introduced in 2013, proposed a single independent regulator but has not been enacted
- National Biotechnology Development Strategy 2021-25: targets making India a global biotech hub within the top 5 nations
- Clinical trial regulation: governed by the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940; the Central Drugs Standard Control Organisation (CDSCO) is the regulatory authority
- India has approximately 700+ FDA-approved pharma plants — the highest number outside the US
- Cell and gene therapies, mRNA platforms, and complex generics (biosimilars) represent the next frontier of India-Switzerland collaboration
Connection to this news: The bilateral discussions on emerging areas like cell and gene therapies and digital health-integrated therapeutics signal a move beyond traditional generic manufacturing toward advanced biotechnology collaboration requiring deeper regulatory harmonisation.
Key Facts & Data
- India is the world's largest generic medicine producer, supplying ~20% of global volume
- India's pharma exports: ~USD 28 billion (2024-25)
- EFTA-India TEPA: USD 100 billion investment commitment over 15 years
- India has ~700+ FDA-approved pharmaceutical manufacturing plants
- Switzerland's pharma sector: home to Roche, Novartis, and other major global pharma companies
- India's biotech sector valued at over USD 80 billion
- Section 3(d) of the Indian Patents Act prevents evergreening — upheld in Novartis v. Union of India (2013)
- Only one compulsory license ever granted in India: Bayer's Nexavar (sorafenib), 2012